Zurcher Kantonalbank Zurich Cantonalbank Purchases 1,967 Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 28.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 8,841 shares of the specialty pharmaceutical company’s stock after acquiring an additional 1,967 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Collegium Pharmaceutical were worth $272,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently modified their holdings of COLL. Pacer Advisors Inc. grew its position in shares of Collegium Pharmaceutical by 68.4% in the 4th quarter. Pacer Advisors Inc. now owns 2,174,718 shares of the specialty pharmaceutical company’s stock valued at $66,938,000 after purchasing an additional 883,380 shares during the period. Assenagon Asset Management S.A. boosted its holdings in shares of Collegium Pharmaceutical by 178.1% in the third quarter. Assenagon Asset Management S.A. now owns 425,630 shares of the specialty pharmaceutical company’s stock valued at $9,513,000 after buying an additional 272,565 shares during the period. Qube Research & Technologies Ltd increased its position in shares of Collegium Pharmaceutical by 713.3% during the third quarter. Qube Research & Technologies Ltd now owns 127,010 shares of the specialty pharmaceutical company’s stock worth $2,839,000 after acquiring an additional 111,394 shares in the last quarter. Loomis Sayles & Co. L P lifted its position in Collegium Pharmaceutical by 32.7% in the 3rd quarter. Loomis Sayles & Co. L P now owns 273,628 shares of the specialty pharmaceutical company’s stock valued at $6,116,000 after acquiring an additional 67,439 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC boosted its stake in Collegium Pharmaceutical by 1,019.0% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 41,670 shares of the specialty pharmaceutical company’s stock worth $931,000 after purchasing an additional 37,946 shares during the period.

Analyst Upgrades and Downgrades

Several research firms have issued reports on COLL. Truist Financial lifted their price target on Collegium Pharmaceutical from $37.00 to $40.00 and gave the company a “buy” rating in a research note on Monday, February 26th. Piper Sandler reissued an “overweight” rating and issued a $39.00 price objective (up previously from $37.00) on shares of Collegium Pharmaceutical in a research report on Friday, February 23rd. StockNews.com downgraded shares of Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, May 1st. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $40.00 price target on shares of Collegium Pharmaceutical in a research note on Thursday, April 11th. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat, Collegium Pharmaceutical presently has an average rating of “Moderate Buy” and a consensus price target of $39.00.

Collegium Pharmaceutical Stock Performance

NASDAQ COLL opened at $37.51 on Monday. Collegium Pharmaceutical, Inc. has a 12 month low of $20.83 and a 12 month high of $40.95. The company has a current ratio of 1.17, a quick ratio of 1.10 and a debt-to-equity ratio of 2.48. The stock has a 50 day moving average of $37.56 and a 200-day moving average of $31.91. The company has a market cap of $1.23 billion, a PE ratio of 31.79 and a beta of 1.06.

Collegium Pharmaceutical (NASDAQ:COLL) last posted its quarterly earnings results on Thursday, February 22nd. The specialty pharmaceutical company reported $1.45 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.20 by $0.25. The firm had revenue of $149.75 million for the quarter, compared to analyst estimates of $147.66 million. Collegium Pharmaceutical had a net margin of 8.50% and a return on equity of 107.39%. On average, equities research analysts anticipate that Collegium Pharmaceutical, Inc. will post 5.63 EPS for the current fiscal year.

Collegium Pharmaceutical Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.